Clinical Trial Update: Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports a completed Phase 1/2 safety trial of PPI-1019 in adults with mild-to-moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PPI-1019 (PPI-1019)

Snippet

Sponsor: PRAECIS Pharmaceuticals Inc. | Conditions: Alzheimer's Disease | Phase 1, Phase 2 | Status: COMPLETED